Metastatic Melanoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Ne

Metastatic Melanoma Pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analyzes DelveInsight.

Metastatic Melanoma Overview:

Melanoma is the third most common skin cancer after basal and squamous cell carcinoma. It ranks as the fifth most common cancer in men and the sixth in women. Metastatic melanoma occurs when cancerous cells spread from the original tumor through the lymphatic system or bloodstream, forming new tumors in other parts of the body, typically in stage 3 or 4. Common metastasis sites include the lymph nodes, lungs, liver, bones, and brain. Symptoms vary depending on the affected area but may include fatigue, swollen lymph nodes, weight loss, breathing difficulties, bone pain, and neurological issues.

Diagnosis begins with a skin examination, followed by a biopsy (punch, excisional, or shave) to assess tumor thickness. If metastasis is suspected, additional tests such as lymph node mapping, CT scans, PET scans, MRI, ultrasound, and blood chemistry studies are conducted.

Metastatic melanoma is challenging to treat, with a five-year survival rate of 66% if it has spread to nearby lymph nodes and 27% if it has reached distant organs. Due to the possibility of undetectable metastases, prognosis worsens as the cancer advances.

Request for a detailed insights report on Metastatic Melanoma pipeline insights @ https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Metastatic Melanoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Melanoma Therapeutics Market.

Key Takeaways from the Metastatic Melanoma Pipeline Report

DelveInsight's Metastatic Melanoma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
In October 2024, Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in T cell-redirecting cancer immunotherapies, announced updated Phase 1b clinical data for ACTengine® IMA203 TCR-T, which targets PRAME in melanoma patients. Additionally, the company provided insights into SUPRAME, an upcoming Phase 3 trial aimed at evaluating IMA203 in metastatic melanoma patients.
In April 2024, Obsidian Therapeutics provided an update on its Phase I first-in-human study of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy for individuals with advanced or metastatic melanoma. Presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, the update included safety data from a median 25-week study follow-up along with detailed efficacy results.
Iin April 2024, Iovance Biotherapeutics announced that clinical data on lifileucel in combination with pembrolizumab for frontline advanced melanoma, along with translational data, will be presented at the 2024 ASCO Annual Meeting.
Key Metastatic Melanoma companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others are evaluating new drugs for Metastatic Melanoma to improve the treatment landscape.
Promising Metastatic Melanoma pipeline therapies in various stages of development include EVX 01, IN 10018, AV MEL 1, and others.

Metastatic Melanoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Metastatic Melanoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Melanoma market.

Download our free sample page report on Metastatic Melanoma pipeline insights @ https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Melanoma Emerging Drugs

EVX 01: Evaxion Biotech
IN 10018: InxMed
AV MEL 1: AiVita Biomedical

Metastatic Melanoma Companies

There are over 75 major companies working on therapies for metastatic melanoma. Among them, Evaxion Biotech has a drug candidate in the most advanced stage of development, specifically Phase II.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Metastatic Melanoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Melanoma Therapies and Key Companies: Metastatic Melanoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Melanoma Pipeline Therapeutic Assessment
• Metastatic Melanoma Assessment by Product Type
• Metastatic Melanoma By Stage
• Metastatic Melanoma Assessment by Route of Administration
• Metastatic Melanoma Assessment by Molecule Type

Download Metastatic Melanoma Sample report to know in detail about the Metastatic Melanoma treatment market @ Metastatic Melanoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Metastatic Melanoma Current Treatment Patterns
4. Metastatic Melanoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Melanoma Late-Stage Products (Phase-III)
7. Metastatic Melanoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Melanoma Discontinued Products
13. Metastatic Melanoma Product Profiles
14. Metastatic Melanoma Key Companies
15. Metastatic Melanoma Key Products
16. Dormant and Discontinued Products
17. Metastatic Melanoma Unmet Needs
18. Metastatic Melanoma Future Perspectives
19. Metastatic Melanoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Melanoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.